These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 12468399)

  • 1. Antibody-based therapy of non-Hodgkin's lymphoma.
    Foran JM
    Best Pract Res Clin Haematol; 2002 Sep; 15(3):449-65. PubMed ID: 12468399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Proteins in haematology].
    Clarenbach RE; Mey U
    Ther Umsch; 2011 Nov; 68(11):610-7. PubMed ID: 22045523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma.
    Fanale MA; Younes A
    Drugs; 2007; 67(3):333-50. PubMed ID: 17335294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma.
    Lundin J; Osterborg A; Brittinger G; Crowther D; Dombret H; Engert A; Epenetos A; Gisselbrecht C; Huhn D; Jaeger U; Thomas J; Marcus R; Nissen N; Poynton C; Rankin E; Stahel R; Uppenkamp M; Willemze R; Mellstedt H
    J Clin Oncol; 1998 Oct; 16(10):3257-63. PubMed ID: 9779699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody therapy in non-Hodgkin's lymphoma: the role of rituximab, 90Y-ibritumomab tiuxetan, and alemtuzumab.
    Fietz T; Thiel E
    Recent Results Cancer Res; 2007; 176():153-63. PubMed ID: 17607923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal antibody therapy in lymphoid malignancies.
    Hainsworth JD
    Oncologist; 2000; 5(5):376-84. PubMed ID: 11040273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy combinations with monoclonal antibodies in non-Hodgkin's lymphoma.
    Kahl B
    Semin Hematol; 2008 Apr; 45(2):90-4. PubMed ID: 18381103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
    Stein R; Qu Z; Chen S; Rosario A; Shi V; Hayes M; Horak ID; Hansen HJ; Goldenberg DM
    Clin Cancer Res; 2004 Apr; 10(8):2868-78. PubMed ID: 15102696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody therapy of lymphoma.
    Illidge TM; Bayne MC
    Expert Opin Pharmacother; 2001 Jun; 2(6):953-61. PubMed ID: 11585011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia.
    Schmitt B; Wendtner CM; Bergmann M; Busch R; Franke A; Pasold R; Schlag R; Hopfinger G; Hiddemann W; Emmerich B; Hallek M
    Clin Lymphoma; 2002 Jun; 3(1):26-35. PubMed ID: 12141952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Monoclonal antibodies in hematology in 2009].
    Bonnet C; Beguin Y; De Prijck B; Witvrouw N; Hustinx R; Fillet G
    Rev Med Liege; 2009; 64(5-6):268-73. PubMed ID: 19642457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hematologic malignancies: new developments and future treatments.
    Cheson BD
    Semin Oncol; 2002 Aug; 29(4 Suppl 13):33-45. PubMed ID: 12170431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders.
    Pangalis GA; Dimopoulou MN; Angelopoulou MK; Tsekouras C; Vassilakopoulos TP; Vaiopoulos G; Siakantaris MP
    Med Oncol; 2001; 18(2):99-107. PubMed ID: 11778765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The future of CD20 monoclonal antibody therapy in B-cell malignancies.
    Czuczman MS; Gregory SA
    Leuk Lymphoma; 2010 Jun; 51(6):983-94. PubMed ID: 20367564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
    Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
    J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ["Magic bullets"--monoclonal antibodies in acute leukemia and non-Hodgkin's lymphoma treatment].
    Łuczyński W; Krawczuk-Rybak M
    Postepy Hig Med Dosw; 2002; 56(6):789-801. PubMed ID: 12669700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alemtuzumab therapy in B-cell lymphoproliferative disorders.
    Moreton P; Hillmen P
    Semin Oncol; 2003 Aug; 30(4):493-501. PubMed ID: 12939718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy in indolent Non-Hodgkin's Lymphoma.
    Amhaz G; Bazarbachi A; El-Cheikh J
    Leuk Res Rep; 2022; 17():100325. PubMed ID: 35663281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New directions in the diagnosis and treatment of chronic lymphocytic leukaemia.
    Schriever F; Huhn D
    Drugs; 2003; 63(10):953-69. PubMed ID: 12699399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
    Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
    Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.